These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6491654)

  • 41. Differential effects of 3-PPP enantiomers on extracellular dopamine concentration in the caudate-putamen and nucleus accumbens of rats.
    See RE
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Dec; 350(6):605-10. PubMed ID: 7708117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
    Martin GE; Williams M; Haubrich DR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
    [No Abstract]   [Full Text] [Related]  

  • 43. trans-N-n-Propyl-7-hydroxy-octahydrobenzo(f)quinoline, a rigid 3-PPP analogue with greater potency but lack of selectivity for dopamine autoreceptors.
    Van Oene JC; Houwing HA; Dijkstra D; Horn AS
    Eur J Pharmacol; 1983 Mar; 87(4):491-5. PubMed ID: 6406238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity.
    Hacksell U; Arvidsson LE; Svensson U; Nilsson JL; Sanchez D; Wikström H; Lindberg P; Hjorth S; Carlsson A
    J Med Chem; 1981 Dec; 24(12):1475-82. PubMed ID: 6796690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation.
    Oberlander C; Boissier JR
    J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Similarities of the effects of apomorphine and 3-PPP on serotonin neurons.
    Lee EH; Geyer MA
    Eur J Pharmacol; 1983 Oct; 94(3-4):297-303. PubMed ID: 6653663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat.
    Amalric M; Koob GF; Creese I; Swerdlow NR
    Life Sci; 1986 Nov; 39(21):1985-93. PubMed ID: 2946915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological properties of presynaptic dopamine receptor agonists.
    Carlsson A
    Psychopharmacology Suppl; 1985; 2():31-8. PubMed ID: 3858802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repeated intravenous cocaine administration: locomotor activity and dopamine D2/D3 receptors.
    Wallace DR; Mactutus CF; Booze RM
    Synapse; 1996 Jul; 23(3):152-63. PubMed ID: 8807743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats.
    Carlsson M; Carlsson A; Eriksson E
    Eur J Pharmacol; 1987 Oct; 142(1):39-43. PubMed ID: 3691635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An automatic device for measuring speed of movement and time spent at rest: its application to testing dopaminergic drugs.
    Schaefer GJ; Bonsall RW; Michael RP
    Physiol Behav; 1986; 37(1):181-6. PubMed ID: 3737717
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Monoamine metabolism in the rat striatum during actions on the nucleus accumbens].
    Saul'skaia NB
    Fiziol Zh Im I M Sechenova; 1996 Feb; 82(2):13-9. PubMed ID: 8768127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
    Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. I. Locomotor activity and behavioral supersensitivity.
    Staunton DA; Magistretti PJ; Shoemaker WJ; Bloom FE
    Brain Res; 1982 Jan; 232(2):391-400. PubMed ID: 6322914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute effect of nicotine on the striatal dopaminergic system in the rat.
    Fung YK; Lau YS
    J Pharm Pharmacol; 1986 Dec; 38(12):920-2. PubMed ID: 2880968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypophysectomy-induced striatal hypersensitivity and mesolimbic hyposensitivity to apomorphine.
    Gordon JH
    Pharmacol Biochem Behav; 1983 Nov; 19(5):807-11. PubMed ID: 6139829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.
    Arnt J; Hyttel J
    J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.